PAD patients may get a boost from a single dose of vumerity

NCT ID NCT06319339

Recruiting now Symptom relief Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a single dose of Vumerity (diroximel fumarate) can improve blood vessel function and walking ability in 20 people aged 50-75 with peripheral artery disease (PAD). Participants will receive either Vumerity or a placebo, and researchers will measure changes in blood flow, oxygen use, and treadmill walking distance. The goal is to see if reducing oxidative stress can ease leg pain and improve mobility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vumerity (diroximel fumarate)
What this could lead to: If it works, this could point toward a new way to improve walking ability and blood vessel function in people with peripheral artery disease.
What could go wrong: This is a very early, small trial with only 20 people, testing just a single dose. The results may not lead to a lasting treatment or apply to everyone with PAD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease peripheral arterial occlusive disease 1 peripheral vascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERIAL DISEASE PERIPHERAL ARTERIAL OCCLUSIVE DISEASE PERIPHERAL ARTERY DISEASE PERIPHERAL VASCULAR DISEASES

Contacts and locations

Locations

University of Nebraska - Omaha
RECRUITING

Omaha, Nebraska, 68182, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.